The year 1985 saw the birth of rivastigmine.1 Rivastigmine, a semi-synthetic derivative of physostigmine, was developed by Prof Marta Weinstock-Rosin of the Department of Pharmacology at the Hebrew University of Jerusalem. For these and other efforts, Prof Weinstock-Rosin was awarded the Israel Prize for Medicine in 2014. After its discovery, rivastigmine was sold by Yissum to Novartis for commercial development.2
In 1997, the Food & Drug Administration (FDA) in the United States approved rivastigmine, a cholinesterase inhibitor, for the treatment...
